Vaccine enhancement through antigen targeting

通过抗原靶向增强疫苗

• 批准号: 6791150
• 负责人: DAVID M WHITE
• 金额: $ 10.4万
• 依托单位: ITERATIVE THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-06-15 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6791150
• 关键词: T lymphocyte; albumins; antibody receptor; antigen presenting cell; biotechnology; immune response; immunoglobulin G; laboratory mouse; peptides; polymers; protein structure function; vaccine development

DESCRIPTION (provided by applicant): There is currently a great need for new and more effective vaccines. Vaccines based on recombinant proteins, purified subunits, or peptides often elicit poor immune responses resulting in a failure to achieve vaccination. Our solution is to develop more effective vaccines that target antigens to antigen presenting cells more directly. In this Phase I proposal we are performing feasibility studies to test the use of FcRLs as a component of vaccines. When used as part of a vaccine, FcRLs effectively target attached antigens to antigen presenting cells. Our Phase I goals are 1) To determine a best adjuvant system and minimum dose necessary for immunization using a weak recombinant antigen, 2) establish efficacy of this system for the use of peptides antigens, 3) to investigate the applicability of using FcRLs as a boost in combination with other current vaccine formulations and 4) characterize FcRL-induced antibody responses. Should Phase I data indicate that better vaccines can be designed using FcRLs, in Phase II we will design a prototype vaccine(s) for delivery of peptide antigens or recombinant subunits. Commercial Potential: Essentially all individuals in the developed world as well as nearly all domesticated animals are currently vaccinated. If new indications could be addressed by better vaccines then the demand for these products would be vast. Equally vast would be the potential benefit to human and animal health and well-being.

描述（由申请人提供）：目前非常需要新的和更有效的疫苗。基于重组蛋白、纯化的亚基或肽的疫苗通常引起不良的免疫应答，导致不能实现疫苗接种。我们的解决方案是开发更有效的疫苗，更直接地将抗原靶向抗原呈递细胞。在第一阶段的提案中，我们正在进行可行性研究，以测试使用FcRL作为疫苗的组成部分。当用作疫苗的一部分时，FcRL有效地将附着的抗原靶向抗原呈递细胞。 我们的I期目标是1）确定使用弱重组抗原进行免疫所需的最佳佐剂系统和最小剂量，2）确定该系统对于使用肽抗原的功效，3）研究使用FcRL作为与其他当前疫苗制剂组合的加强的适用性，以及4）表征FcRL诱导的抗体应答。 如果I期数据表明可以使用FcRL设计更好的疫苗，则在II期中，我们将设计用于递送肽抗原或重组亚基的原型疫苗。 商业潜力：基本上所有发达国家的个体以及几乎所有驯养动物目前都接种了疫苗。如果新的适应症可以通过更好的疫苗来解决，那么对这些产品的需求将是巨大的。对人类和动物健康和福祉的潜在益处同样巨大。